New pharmacological developments in the treatment of hepatocellular cancer.

Drugs
Niraj J GusaniJaffer A Ajani

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm and fourth leading cause of cancer death worldwide. The survival for patients with advanced HCC is extremely poor. This is largely attributed to the lack of effective screening methods, advanced stage at presentation, limited utility of surgical intervention and ineffective medical therapy. Over the past 30 years, many conventional cytotoxic agents have been tested and have failed to confer a survival benefit. Recently, sorafenib, a multi-tyrosine kinase inhibitor, was approved by the US FDA as first-line therapy in HCC as the first agent demonstrating survival benefit in this disease. Although the survival benefit demonstrated by sorafenib is moderate, molecular targeted therapy has brought new hope in the management of HCC.

References

Dec 1, 1995·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N FaustoE M Webber
Mar 1, 1996·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M MiseM Imamura
Feb 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R G SimonettiL Pagliaro
Jul 10, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R YamaguchiM Kojiro
Mar 11, 1999·The New England Journal of Medicine·H B El-Serag, A C Mason
Mar 31, 2000·Journal of Cancer Research and Clinical Oncology·F Q AnY Matsumoto
Sep 18, 2004·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Margarita SalaUNKNOWN Barcelona Clinic Liver Cancer (BCLC) Group
Nov 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·S ColnotC Perret
Apr 15, 2005·Journal of Gastroenterology·Josep M Llovet
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip A PhilipCharles Erlichman
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew X ZhuKeith Stuart
Apr 25, 2006·Liver International : Official Journal of the International Association for the Study of the Liver·Hiroshi WadaMorito Monden
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Sep 29, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Joanna W Y HoRonnie T P Poon
Jul 12, 2007·Cancer·Melanie B ThomasJames L Abbruzzese
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert G GishGerard T Kennealey
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abby B SiegelJonathan D Schwartz
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Nov 26, 2008·World Journal of Gastroenterology : WJG·Thomas YauRonnie-T Poon
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melanie B ThomasJames Abbruzzese
Jan 27, 2009·Cancer Chemotherapy and Pharmacology·Ramesh K RamanathanDavid R Gandara

❮ Previous
Next ❯

Citations

Jan 20, 2011·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Rongping ZhouXiaochun Bai

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.